2. Search Result
Search Result
Results for "

Ttk Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-101340
    Luvixasertib
    5+ Cited Publications

    CFI-402257

    		 Mps1 Cancer
    CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity .
    Luvixasertib
  • HY-14710
    AZ3146
    Maximum Cited Publications
    11 Publications Verification

    		 Mps1 Cancer
    AZ3146 is a reasonably potent Mps1 and TTK inhibitor, with IC50 of 35 nM for Mps1 Cat.
    AZ3146
  • HY-101340A
    Luvixasertib hydrochloride
    5+ Cited Publications

    CFI-402257 hydrochloride

    		 Mps1 Cancer
    CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity .
    Luvixasertib hydrochloride
  • HY-108709
    CC-671
    1 Publications Verification

    		 CDK Cancer
    CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
    CC-671
  • HY-100024
    NTRC 0066-0

    		Mps1 Cancer
    NTRC 0066-0 is a selective threonine tyrosine kinase (TTK) inhibitor (IC50=0.9 nM). NTRC 0066-0 can be used for the research of cancer .
    NTRC 0066-0
  • HY-132884
    TTK inhibitor 3

    		Mps1 Cancer
    TTK inhibitor 3 is a potent and selective TTK (an essential spindle assembly checkpoint enzyme) inhibitor with an IC50 value of 3.0 nM.
    TTK inhibitor 3
  • HY-164955
    TTK/PLK1-IN-1

    		Mps1 Polo-like Kinase (PLK) Cancer
    TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC .
    TTK/PLK1-IN-1
  • HY-144308
    RMS-07

    		Mps1 Others
    RMS-07 is a covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor, with an apparent IC50 of 13.1 nM. RMS-07 targets a poorly conserved cysteine in the kinase's hinge region .
    RMS-07
  • HY-123675
    CFI-400936

    		Mps1 Cancer
    CFI-400936 is a potent TTK inhibitor with an IC50 of 3.6 nM. CFI-400936 has antitumor activity .
    CFI-400936
  • HY-162156
    TTK inhibitor 4

    		Mps1 Cancer
    TTK inhibitor 4 (compound 16) is a potent inhibitor of threonine tyrosine kinase (TTK), with the IC50 value of 0.016 μM, that has anti-tumor activity .
    TTK inhibitor 4
  • HY-149213
    LSD1/TLK1-IN-1

    J54; J3-54

    		 Histone Demethylase TLK Apoptosis PD-1/PD-L1 Cancer
    LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .
    LSD1/TLK1-IN-1
  • HY-160419
    Mps1-IN-8

    		Mps1 Cancer
    Mps1-IN-8 is a Mps1 inhibitor. Mps1-IN-8 can be used in the study of various tumors .
    Mps1-IN-8
  • HY-116190
    CFI-401870

    		Mps1 DNA/RNA Synthesis Cancer
    CFI-401870 is an orally active threonine tyrosine kinase (TTK (Mps1)) inhibitor with an IC50 of 3.1 nM. CFI-401870 exhibits IC50s against PLK4, KDR, AURKA and other kinases such as AURKB/INCENP were all greater than 1 μM.CFI-401870 inhibits the growth of various cancer cells, causing chromosome lag, an increase in aneuploidy and cell cycle arrest. CFI-401870 can be used for the study of cancers such as colon cancer .
    CFI-401870
  • HY-179430
    TTK-IN-5

    		Mps1 Cancer
    TTK-IN-5 is an orally active covalent threonine tyrosine kinase (TTK) inhibitor with selectivity (IC50 = 8.918 nM). TTK-IN-5 exhibits anti-proliferative potencies against MDA-MB-231, A2780, HCT116, HCC1569 and MKN1 cell lines (IC50 values of 0.113 μM, 0.476 μM, 3.136 μM, 3.649 μM, and 1.856 μM, respectively). TTK-IN-5 potently suppresses tumor growth without notable toxicity in A2780 and MDA-MB-231 xenograft mouse models. TTK-IN-5 can be used for the research of cancer such as breast cancer and ovarian cancer .
    TTK-IN-5
  • HY-101340AR
    Luvixasertib hydrochloride (Standard)

    CFI-402257 hydrochloride (Standard)

    		 Mps1 Reference Standards Cancer
    Luvixasertib (hydrochloride) (Standard) is the analytical standard of Luvixasertib (hydrochloride) (HY-101340A). This product is intended for research and analytical applications. CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity .
    Luvixasertib hydrochloride (Standard)
  • HY-108709R
    CC-671 (Standard)

    		Reference Standards CDK Cancer
    CC-671 (Standard) is the analytical standard of CC-671 (HY-108709). This product is intended for research and analytical applications. CC-671 is a dual TTK protein Kinase/CDC2-like Kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
    CC-671 (Standard)
  • HY-116470
    Mps1/TTK-IN-1

    		Mps1 Cancer
    Mps1/TTK-IN-1 (Compound cpd-5), a derivative of NMS-P715 (HY-12382), is a Mps1 kinase inhibitor with an IC50 of 9.2 nM and a Kd of 1.6 nM. Mps1/TTK-IN-1 specifically targets the ATP-binding pocket of the Mps1 kinase. Mps1/TTK-IN-1 maintains inhibitory activity against Mps1 drug-resistant mutants (C604Y, C604W) with IC50 values of 170 and 19 nM and Kd values of 471 and 349 nM. Mps1/TTK-IN-1 can block the phosphorylation of kinetochore protein KNL1 mediated by Mps1, interfere with the spindle assembly checkpoint function, prevent the correct separation of chromosomes, and thereby inhibit the mitosis and proliferation of tumor cells .
    Mps1/TTK-IN-1
  • HY-182928
    LRRK2-IN-21

    		LRRK2 Mps1 Neurological Disease
    LRRK2-IN-21 is a selective, blood-brain barrier-permeable LRRK2 kinase inhibitor with an IC50 of 0.35 nM. LRRK2-IN-21 inhibits TTK kinase with an IC50 of 70 nM. LRRK2-IN-21 is applicable to the research of Parkinson's disease .
    LRRK2-IN-21

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: